Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced a share buyback transaction, purchasing 991,883 ordinary shares for cancellation as part of its ongoing buyback program. This move reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value, impacting the number of shares with voting rights to 8,990,513,705.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score is driven by its strong financial performance and positive earnings outlook. However, overvaluation concerns and mixed technical indicators temper the score. The company’s proactive capital management through share buybacks further supports its market standing.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 27,158,020
Technical Sentiment Signal: Buy
Current Market Cap: £35.16B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.